US-based diagnostics firm PerkinElmer has rolled out the Cellaca PLX Image Cytometry System, designed by the company’s subsidiary Nexcelom Bioscience.

The benchtop cytometry platform combines advanced image cytometer hardware, software, validated consumables and trackable data reporting, all in a single system

It enables researchers to evaluate multiple Critical Quality Attributes (CQAs) of cell samples, including cell identity, quality and quantity, in a single automated workflow.

PerkinElmer said the cytometry system also eliminates the need for complex calibration procedures or intense training requirements.

PerkinElmer Life Sciences senior vice president Alan Fletcher said: “Pharmaceutical companies have invested heavily in cell and gene therapy, but they struggle to assess the complex cell samples required to meet immense scientific demands and regulatory rigour across their research and manufacturing processes.

“While the Cellaca PLX Image Cytometer platform is therapeutic area agnostic, it is expected to be especially beneficial for researchers working in CAR-T cell therapy who want to streamline their phenotyping of immune cells for downstream processes.”

The Cellaca PLX system leverages optimised reagent kits with validated antibodies from PerkinElmer’s BioLegend business, to further streamline the customer experience.

PerkinElmer stated that its new offering will provide researchers with expanded cell sample CQA analysis options beyond flow cytometry and staining methods.

The CQA analysis traditionally required different instruments and analytical methods.

The researchers can now perform immunophenotyping and viability assays, and detect multiple markers simultaneously within seconds, said the company.

Last year, PerkinElmer acquired Nexcelom for a total consideration of $260m in cash.

Nexcelom provides automated cell counting technology and image cytometry products for cell analysis, including Cellaca MX high-throughput automated cell counter.